Compare AbCellera Biologics Inc (ABCL) vs National Beverage Corp. (FIZZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs National Beverage Corp. — how do they compare? AbCellera Biologics Inc trades at $10.28 (market cap $2.99B), while National Beverage Corp. trades at $30.9 (market cap $2.89B). The key difference: AbCellera Biologics Inc and National Beverage Corp. are close in size by market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, National Beverage Corp. nearer its low. Which is the better fit depends on your goals.
| ABCL | FIZZ | |
|---|---|---|
Market Cap | $2.99B | $2.89B |
Sector | Health | Consumer Cyclical |
52-Week High | $9.76 | $46.75 |
52-Week Low | $2.78 | $30.53 |
Enterprise Value | $2.58B | $2.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $10.34, up 10.71% on positive Phase 2 trial results for its menopause drug ABCL635, which showed 83% reduction in hot flashes. Despite negative profitability metrics, the stock maintains strong analyst support with 91.7% buy ratings and a $15.50 consensus target. Technical indicators show bullish momentum with the price near resistance at $11, though RSI levels suggest overbought conditions.
The outlook remains speculative given ongoing losses but is supported by promising clinical data and strategic partnerships. Key risks include drug development timelines, cash burn, and reliance on successful commercialization. Upside potential exists if ABCL635 advances successfully through regulatory phases.
FIZZ trades at $30.60, down 1.42% on the day, with bearish technical signals dominating. The stock shows mixed fundamentals with strong profitability metrics including 37% gross margins and 34% ROE, but faces growth challenges as revenue has stagnated around $1.2B annually. Recent earnings have missed expectations in three of the last four quarters, while the company maintains dividend payments with a recent $3.25 special dividend declaration.
The outlook remains cautious given stalled revenue growth and bearish analyst sentiment with 50% sell ratings. While valuation appears reasonable at 15.7x P/E, competitive pressures in the sparkling water market and declining LaCroix volumes present significant headwinds. The stock's current technical weakness near support levels suggests continued pressure unless fundamental catalysts emerge.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About National Beverage Corp.
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →
